Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary ImmunoGen Presents Updated Findings from Phase 1 Study of IMGN632 at ASH Annual Meeting
Data Demonstrating Potential in AML and BPDCN Presented During Oral Presentation; Dose and Schedule Selected for Further Development Preclinical Combination Data Also Presented; Support Further Evaluation of IMGN632 Doublets and Triplet in AML WALTHAM, Mass. --(BUSINESS WIRE)--Dec.
View HTML
Toggle Summary ImmunoGen Presents Updated Findings from CADENZA Trial of Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm at EHA 2023 Congress
Interim Analysis from Phase 2 Trial Demonstrates Compelling Anti-Tumor Activity in Patients with Frontline and Relapsed/Refractory BPDCN; No New Safety Signals Identified Enrollment Continues in Frontline CADENZA Cohort; Top-Line Pivotal Data Expected in 2024 WALTHAM, Mass. --(BUSINESS WIRE)--Jun.
View HTML
Toggle Summary ImmunoGen Presents Retrospective Analysis of Extended Treatment Benefit from Multiple Trials of Mirvetuximab Soravtansine in Ovarian Cancer at ESGO
Patients with Extended Treatment Benefit Showed an Objective Response Rate of 77.5% and a Median Duration of Response of 22.1 Months Overall Adverse Event Profile Observed Consistent with Known Safety Profile of Mirvetuximab with Minimal Cumulative Toxicities Study Outcomes in Patients with
View HTML
Toggle Summary ImmunoGen Presents Preclinical Data on IMGN151 at Virtual AACR Annual Meeting
Next Generation FRα-Targeting ADC Engineered to Maximize Potential Clinical Benefit for Patients with Lower FRα Expression Potent Anti-Tumor Activity Exhibited in Ovarian Cancer and Other Tumor Types Regardless of FRα Expression Level WALTHAM, Mass. --(BUSINESS WIRE)--Jun.
View HTML
Toggle Summary ImmunoGen Presents Preclinical Data on IMGC936 at the AACR Virtual Annual Meeting
First-in-Class ADAM9-Targeting ADC Demonstrates Anti-Tumor Activity in Multiple Solid Tumor Models WALTHAM, Mass. --(BUSINESS WIRE)--Apr. 10, 2021-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that a
View HTML
Toggle Summary ImmunoGen Presents New Data Highlighting Potential of Novel ADCs in Oral Presentations at ASH Annual Meeting
Initial Data for CD123-Targeting IMGN632 Demonstrate Encouraging Anti-Leukemia Activity and Tolerable Safety Profile in Both AML and BPDCN; Dose Exploration Continues Maturing Data for CD33-Targeting IMGN779 Reflect Consistent Activity and Tolerability Profile in AML; Dose Exploration Continues
View HTML
Toggle Summary ImmunoGen Presents New Clinical and Preclinical Data at ASH Annual Meeting
CD33-Targeting IMGN779 Demonstrates Favorable Safety Profile and Anti-Leukemia Activity in Ongoing Phase 1 Trial; Dose Escalation Continues with Two Dosing Schedules Preclinical Data Presentations on IMGN779 in Combination and CD123-Targeting IMGN632 Highlight Breadth of ImmunoGen Hematology
View HTML
Toggle Summary ImmunoGen Presents Initial Findings From the Phase 1b/2 Study of IMGN632 in Combination With Vidaza® and Venclexta® in Relapsed/Refractory Acute Myeloid Leukemia at ASH
Triplet Data Demonstrating Manageable Safety Profile and Promising Anti-Leukemia Activity Highlighted in Oral Presentation Expansion Cohorts in Relapsed and Frontline AML Planned Data for IMGN632 in Three Frontline BPDCN Patients Also Presented in Poster Presentation Showing Clinical Complete
View HTML
Toggle Summary ImmunoGen Presents Initial Data from Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab Soravtansine in Combination with Carboplatin and Avastin® at ESMO
  FORWARD II Triplet Combination Demonstrates Encouraging Anti-Tumor Activity     Preliminary Findings Support Ongoing Study in Platinum-Sensitive Patients     WALTHAM, Mass. --(BUSINESS WIRE)--Sep. 29, 2019-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug
View HTML
Toggle Summary ImmunoGen Presents Initial Data from FORWARD II Expansion Cohort Assessing Mirvetuximab Soravtansine in Combination with KEYTRUDA at ESMO 2018 Congress
Preliminary Data Demonstrate Favorable Safety Profile and Encouraging Activity in Heavily Pretreated Patients with Ovarian Cancer WALTHAM, Mass. --(BUSINESS WIRE)--Oct. 20, 2018-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment
View HTML